Serum anticholinergicity in elderly depressed patients treated with paroxetine or nortriptyline. 1998

B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
Department of Psychiatry, University of Pittsburgh School of Medicine, PA, USA. pollockbg@msx.upmc.edu

OBJECTIVE The authors' goal was to compare serum anticholinergicity of 61 elderly depressed patients randomly assigned to double-blind treatment with paroxetine (N=31) or nortriptyline (N=30). METHODS Both antidepressants were titrated in a standardized manner, and plasma was sampled weekly for measurement of paroxetine and nortriptyline and its hydroxy metabolite concentrations. Serum anticholinergicity was measured at baseline and after 1, 4, and 6 weeks of treatment. Side effects were assessed by using a validated scale. RESULTS After correcting for pretreatment anticholinergicity, the authors found that mean serum anticholinergicity for the nortriptyline-treated patients was significantly greater than that for the paroxetine group at all weeks assessed. Serum anticholinergicity was significantly correlated with nortriptyline but not with paroxetine plasma levels. Complaints of dry mouth and tachycardia were significantly more frequent and severe in the nortriptyline group. CONCLUSIONS These findings suggest that, at therapeutic plasma concentrations, paroxetine has approximately one-fifth the anticholinergic potential of nortriptyline in older patients.

UI MeSH Term Description Entries
D009661 Nortriptyline A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions. Desitriptyline,Desmethylamitriptylin,Allegron,Apo-Nortriptyline,Aventyl,Gen-Nortriptyline,Norfenazin,Nortrilen,Nortriptyline Hydrochloride,Novo-Nortriptyline,Nu-Nortriptyline,PMS-Nortriptyline,Pamelor,Paxtibi,ratio-Nortriptyline,Apo Nortriptyline,Gen Nortriptyline,Hydrochloride, Nortriptyline,Novo Nortriptyline,Nu Nortriptyline,PMS Nortriptyline,ratio Nortriptyline
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D013610 Tachycardia Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia. Tachyarrhythmia,Tachyarrhythmias,Tachycardias
D014987 Xerostomia Decreased salivary flow. Asialia,Hyposalivation,Mouth Dryness,Asialias,Dryness, Mouth,Hyposalivations,Xerostomias
D017374 Paroxetine A serotonin uptake inhibitor that is effective in the treatment of depression. Aropax,BRL-29060,FG-7051,Paroxetine Acetate,Paroxetine Hydrochloride,Paroxetine Hydrochloride Anhydrous,Paroxetine Hydrochloride Hemihydrate,Paroxetine Hydrochloride, Hemihydrate,Paroxetine Maleate,Paroxetine, cis-(+)-Isomer,Paroxetine, cis-(-)-Isomer,Paroxetine, trans-(+)-Isomer,Paxil,Seroxat,BRL 29060,BRL29060,FG 7051,FG7051
D018680 Cholinergic Antagonists Drugs that bind to but do not activate CHOLINERGIC RECEPTORS, thereby blocking the actions of ACETYLCHOLINE or cholinergic agonists. Acetylcholine Antagonist,Acetylcholine Antagonists,Anti-Cholinergic,Anticholinergic,Anticholinergic Agent,Anticholinergic Agents,Cholinergic Receptor Antagonist,Cholinergic-Blocking Agent,Cholinergic-Blocking Agents,Cholinolytic,Cholinolytics,Anti-Cholinergics,Anticholinergics,Cholinergic Antagonist,Cholinergic Receptor Antagonists,Agent, Anticholinergic,Agent, Cholinergic-Blocking,Agents, Anticholinergic,Agents, Cholinergic-Blocking,Antagonist, Acetylcholine,Antagonist, Cholinergic,Antagonist, Cholinergic Receptor,Antagonists, Acetylcholine,Antagonists, Cholinergic,Antagonists, Cholinergic Receptor,Anti Cholinergic,Anti Cholinergics,Cholinergic Blocking Agent,Cholinergic Blocking Agents,Receptor Antagonist, Cholinergic,Receptor Antagonists, Cholinergic

Related Publications

B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
March 2003, European psychiatry : the journal of the Association of European Psychiatrists,
B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
May 1992, Progress in neuro-psychopharmacology & biological psychiatry,
B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
May 2000, The American journal of cardiology,
B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
January 1998, JAMA,
B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
April 2000, Journal of clinical psychopharmacology,
B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
February 2016, Parkinsonism & related disorders,
B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
May 2001, Journal of the American Academy of Child and Adolescent Psychiatry,
B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
January 1989, Acta psychiatrica Scandinavica. Supplementum,
B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
August 1991, Journal of clinical psychopharmacology,
B G Pollock, and B H Mulsant, and R Nebes, and M A Kirshner, and A E Begley, and S Mazumdar, and C F Reynolds
September 2000, The international journal of neuropsychopharmacology,
Copied contents to your clipboard!